EverHint – Breakout Standard, Cap Large Only, Sector Tech, Sector Healthcare, Volatile High Beta, Breakout Ultra Tight – Top 7 Signals for Nov 13, 2026
Excerpt: 7 signals. Healthcare leads (4). price range $34-$36. 1 with insider selling.
Breakout Standard
Stocks within 3% of 52-week high - standard breakout momentum setups. Stock showing strong momentum near or at highs. Increased volume confirms institutional interest. Breaking out or consolidating near resistance.
Entry Criteria:
- Strong RSI momentum
- Volume surge above average
- Within 3% of 52-week high
- Minimum ADV: $25M+
- Earnings buffer: 7 days
Holding period: 1-4 weeks | Risk level: Medium-High
📊 Signals (2 of 2)
Ranked by composite momentum score
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | CHYM | Chime Financial, Inc. ... | Technology | $33.55 | 0.30 | Sell -$8,291 | $12.7B |
| 2 | PCRX | Pacira BioSciences, Inc. | Healthcare | $36.46 | 0.00 | — | $1.5B |
Insider selling (7d): CHYM (-$8,291)
Cap Large Only
High momentum stock screener for swing trading opportunities. Identifies stocks with strong momentum characteristics suitable for swing trading (1-4 week holds). Includes multiple variants: breakout, pullback, aggressive momentum, and volatile high-beta.
Entry Criteria:
- Strong RSI momentum (configurable thresholds)
- Volume surge above average
- Price momentum confirmation
- Minimum ADV: $25M+ (varies by variant)
- Earnings buffer: 7 days pre/post earnings
- Variant-specific filters applied
Holding period: 1-4 weeks | Risk level: Medium-High
📊 Signals (1 of 1)
Ranked by composite momentum score (higher = stronger momentum)
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | CHYM | Chime Financial, Inc. ... | Technology | $33.55 | 0.00 | Sell -$8,291 | $12.7B |
Insider selling (7d): CHYM (-$8,291)
Sector Tech
High momentum stock screener for swing trading opportunities. Identifies stocks with strong momentum characteristics suitable for swing trading (1-4 week holds). Includes multiple variants: breakout, pullback, aggressive momentum, and volatile high-beta.
Entry Criteria:
- Strong RSI momentum (configurable thresholds)
- Volume surge above average
- Price momentum confirmation
- Minimum ADV: $25M+ (varies by variant)
- Earnings buffer: 7 days pre/post earnings
- Variant-specific filters applied
Holding period: 1-4 weeks | Risk level: Medium-High
📊 Signals (1 of 1)
Ranked by composite momentum score (higher = stronger momentum)
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | CHYM | Chime Financial, Inc. ... | Technology | $33.55 | 0.00 | Sell -$8,291 | $12.7B |
Insider selling (7d): CHYM (-$8,291)
Sector Healthcare
High momentum stock screener for swing trading opportunities. Identifies stocks with strong momentum characteristics suitable for swing trading (1-4 week holds). Includes multiple variants: breakout, pullback, aggressive momentum, and volatile high-beta.
Entry Criteria:
- Strong RSI momentum (configurable thresholds)
- Volume surge above average
- Price momentum confirmation
- Minimum ADV: $25M+ (varies by variant)
- Earnings buffer: 7 days pre/post earnings
- Variant-specific filters applied
Holding period: 1-4 weeks | Risk level: Medium-High
📊 Signals (1 of 1)
Ranked by composite momentum score (higher = stronger momentum)
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | PCRX | Pacira BioSciences, Inc. | Healthcare | $36.46 | 0.00 | — | $1.5B |
Volatile High Beta
High momentum stock screener for swing trading opportunities. Identifies stocks with strong momentum characteristics suitable for swing trading (1-4 week holds). Includes multiple variants: breakout, pullback, aggressive momentum, and volatile high-beta.
Entry Criteria:
- Strong RSI momentum (configurable thresholds)
- Volume surge above average
- Price momentum confirmation
- Minimum ADV: $25M+ (varies by variant)
- Earnings buffer: 7 days pre/post earnings
- Variant-specific filters applied
Holding period: 1-4 weeks | Risk level: Medium-High
📊 Signals (1 of 1)
Ranked by composite momentum score (higher = stronger momentum)
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | PCRX | Pacira BioSciences, Inc. | Healthcare | $36.46 | 0.00 | — | $1.5B |
Breakout Ultra Tight
High momentum stock screener for swing trading opportunities. Identifies stocks with strong momentum characteristics suitable for swing trading (1-4 week holds). Includes multiple variants: breakout, pullback, aggressive momentum, and volatile high-beta.
Entry Criteria:
- Strong RSI momentum (configurable thresholds)
- Volume surge above average
- Price momentum confirmation
- Minimum ADV: $25M+ (varies by variant)
- Earnings buffer: 7 days pre/post earnings
- Variant-specific filters applied
Holding period: 1-4 weeks | Risk level: Medium-High
📊 Signals (1 of 1)
Ranked by composite momentum score (higher = stronger momentum)
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | PCRX | Pacira BioSciences, Inc. | Healthcare | $36.46 | 0.00 | — | $1.5B |
Recent Headlines
CHYM (Chime Financial, Inc. Class A Common Stock)
- Chime Financial Set to Join S&P MidCap 400
- Chime: Strong Q3, But Priced Above Peers
- Chime to Participate in UBS Global Technology and AI Conference
- Chime Financial, Inc. (CHYM) Presents at KBW Fintech Ecosystem Conference 2026 Transcript
- Chime and Affirm Show the Trade-Offs Behind Credit Growth
- Surging Earnings Estimates Signal Upside for Chime Financial, Inc. (CHYM) Stock
- Why Chime Financial, Inc. (CHYM) is a Top Momentum Stock for the Long-Term
- DST Global Advisors sells $41.4M Chime Financial (NASDAQ:CHYM) stock
PCRX (Pacira BioSciences, Inc.)
- Ingram Micro Holding Set to Join S&P SmallCap 600
- Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT?
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 If this added value to your research, consider liking, sharing, or subscribing. It genuinely helps.